Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid Beta-Peptide in Patients with Alzheimer’s Disease

Publication Date: 

Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, Wienrich M, Raschig A, Deng M, Growdon JH and Nitsch, RM (2001). Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with alzheimer’s disease. Annals NY Acad Sci; 920: 285-291.